These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 20942668)

  • 1. Tanezumab for the treatment of pain from osteoarthritis of the knee.
    Lane NE; Schnitzer TJ; Birbara CA; Mokhtarani M; Shelton DL; Smith MD; Brown MT
    N Engl J Med; 2010 Oct; 363(16):1521-31. PubMed ID: 20942668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study.
    Nagashima H; Suzuki M; Araki S; Yamabe T; Muto C;
    Osteoarthritis Cartilage; 2011 Dec; 19(12):1405-12. PubMed ID: 22004765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain.
    Schnitzer TJ; Lane NE; Birbara C; Smith MD; Simpson SL; Brown MT
    Osteoarthritis Cartilage; 2011 Jun; 19(6):639-46. PubMed ID: 21251985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
    Schnitzer TJ; Khan A; Bessette L; Davignon I; Brown MT; Pixton G; Prucka WR; Tive L; Viktrup L; West CR
    Semin Arthritis Rheum; 2020 Jun; 50(3):387-393. PubMed ID: 32252976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
    Berenbaum F; Langford R; Perrot S; Miki K; Blanco FJ; Yamabe T; Isogawa N; Junor R; Carey W; Viktrup L; West CR; Brown MT; Verburg KM
    Eur J Pain; 2021 Aug; 25(7):1525-1539. PubMed ID: 33728717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
    J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
    Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
    Ekman EF; Gimbel JS; Bello AE; Smith MD; Keller DS; Annis KM; Brown MT; West CR; Verburg KM
    J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
    Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials.
    Fan ZR; Ma JX; Wang Y; Chen HT; Lang S; Ma XL
    Clin Rheumatol; 2021 Jun; 40(6):2155-2165. PubMed ID: 33159281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
    Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z
    Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis.
    Kan SL; Li Y; Ning GZ; Yuan ZF; Chen LX; Bi MC; Sun JC; Feng SQ
    PLoS One; 2016; 11(6):e0157105. PubMed ID: 27294371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.
    Berenbaum F; Schnitzer T; Kivitz A; Viktrup L; Johnston E; Yang R; Whalen E; Tive L; Semel D
    Int J Clin Pract; 2021 Dec; 75(12):e14975. PubMed ID: 34626502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.
    Brown MT; Cornblath DR; Koltzenburg M; Gorson KC; Hickman A; Pixton GC; Gaitonde P; Viktrup L; West CR
    Clin Drug Investig; 2023 Jul; 43(7):551-563. PubMed ID: 37460782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome.
    Nickel JC; Atkinson G; Krieger JN; Mills IW; Pontari M; Shoskes DA; Crook TJ
    Urology; 2012 Nov; 80(5):1105-10. PubMed ID: 23010344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.